On May 1, 2015 Eleison Pharmaceuticals LLC, a specialty pharmaceutical company developing life-saving therapeutics for rare cancers reported that it has successfully completed the first stage of its Phase II study of ILC (Inhaled Lipid-complexed Cisplatin), for the treatment of patients with pediatric osteosarcoma (bone cancer), with all 19 patients enrolled in this stage of the study having reached the study endpoint (Press release, Eleison Pharmaceuticals, MAY 1, 2015, View Source [SID1234517397]). The study has been enrolling patients at 15 of the leading U.S. hospitals and medical centers. More information about the study may be found at the www.clinicaltrials.gov website.
"In this study, we were evaluating if ILC may delay or prevent further pulmonary relapses in osteosarcoma patients", commented Mr. Edwin Thomas, CEO of Eleison. "We are very encouraged by the data generated by the study as 13 of the 19 patients experienced a relapse-free interval longer than the predicted relapse-free interval", further commented Mr. Thomas. Eleison is continuing to evaluate the study data and is planning to commence a pivotal registrational clinical trial of ILC later this year.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!